WallStSmart

Alamar Biosciences, Inc. Common Stock (ALMR)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 23971% more annual revenue ($20.98B vs $87.16M). GEHC leads profitability with a 9.1% profit margin vs -49.9%. GEHC earns a higher WallStSmart Score of 57/100 (C).

ALMR

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -1.23

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALMR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
98.9%10/10

Revenue surging 98.9% year-over-year

Debt/EquityHealth
-1.9110/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

ALMR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.52B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-33.6%2/10

ROE of -33.6% — below average capital efficiency

Free Cash FlowQuality
$-20.95M2/10

Negative free cash flow — burning cash

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ALMR

The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 98.9% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : ALMR

The primary concerns for ALMR are EPS Growth, Market Cap, Return on Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ALMR profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

ALMR is growing revenue faster at 98.9% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (57/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alamar Biosciences, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases, leveraging its proprietary technologies to enhance patient care and treatment outcomes. The company's advanced platform offers rapid and accurate testing capabilities aimed at significantly improving clinical decision-making processes. With a strong commitment to research and development, Alamar is poised to address unmet medical needs within the healthcare sector, presenting an attractive opportunity for institutional investors looking to capitalize on the growth potential in the diagnostics market.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?